Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. [electronic resource]
Producer: 20110621Description: 1270-7 p. digitalISSN:- 1532-1827
- Animals
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Bevacizumab
- Carcinoma -- pathology
- Cell Line, Tumor
- Cell Movement -- drug effects
- Colorectal Neoplasms -- pathology
- Drug Resistance, Neoplasm -- drug effects
- HCT116 Cells
- Humans
- Mice
- Mice, Nude
- Neoplasm Metastasis
- Signal Transduction -- drug effects
- Time Factors
- Transplantation, Heterologous
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.